Astellas' Zolbetuximab BLA Resubmission Acknowledged by U.S. FDA
Thursday, 30 May 2024, 23:40
Astellas' Zolbetuximab BLA Resubmission
The U.S. FDA has acknowledged Astellas' resubmission of the biologics license application for Zolbetuximab, setting a new action date. This update signals progress in the regulatory process for the promising biologic.
Investors and stakeholders await the FDA's decision on this key development in Astellas' pipeline.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.